Ondine Biomedical is Recipient of the TAYYABA HASAN IMPACT AWARD at 18th IPA World Congress, Finland
17 Jul 2023
Immunotherapy
VANCOUVER, Canada--(BUSINESS WIRE)-- Ondine Biomedical was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Tampere, Finland for demonstrating exceptional perseverance and clinical acumen. Ondine has demonstrated successful outcomes in a number of key studies for both prevention and treatment against strains of SARS-CoV-2 including deployment in large scale enterprises.
The IPA promotes the benefits of light-activated therapies to treat infections that pose the biggest threats to global health security. The IPA World Congress featured research on a number of areas that use light-activated photosensitizers, including photodynamic therapy (PDT), antimicrobial photodisinfection, photoimmunotherapy (PIT), photodiagnosis (PD), etc.
Newly elected President of the IPA Board of Directors, Colin Hopper of UCL, commented, “The international Congress recognizes leaders from around the world, in their respective fields, for their contributions that continue to advance the field of photomedicine. The IPA wishes to congratulate the Ondine team for being recognized as the 2023 recipient of the Tayyaba Hasan IMPACT Award.
“This Team Award recognizes the collective efforts and successes in advancing the clinical safety and efficacy of Photodynamic Therapy for antiviral applications during the COVID-19 pandemic. The outcomes of this work and these studies will help to serve future pandemic preparedness and support the ongoing efforts for advanced antimicrobial resistance stewardship. Antimicrobial resistance is one of the top human health issues globally.”
Ondine team member, Cristina Romo, Senior Scientist and Lab Manager, was honored as an Early Investigator’s Award recipient.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
The International Photodynamic Association (IPA)
The International Photodynamic Association (IPA) was founded in 1986 to support and endorse the scientific advancement and clinical development of photomedicine, in particular in the areas of photodynamic disinfection, photodynamic therapy (PDT), photoimmunotherapy (PIT), and photodiagnosis (PD).
View source version on businesswire.com:
Contacts
Vane Percy & Roberts
Simon Vane Percy, Amanda Bernard
+44 (0)77 1000 5910
simon@vanepercy.com
Source: Ondine Biomedical
View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.